

Belimumab combined with standard therapy does not increase adverse effects compared with a control treatment: A systematic review and meta-analysis of randomised controlled trials

Xu Y, Xu JW, Wang YJ, Tung TH, Chien CW.

International immunopharmacology

2022; 109:e108811

ARTICLE IDENTIFIERS

DOI: 10.1016/j.intimp.2022.108811

PMID: 35512563

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: 2001220027

pISSN: 1567-5769

eISSN: 1878-1705

OCLC ID: 45956485

CONS ID: not available

US National Library of Medicine ID: 100965259

This article was identified from a query of the SafetyLit database.